MiMedx up 6% premarket on positive data on dHUC in diabetic foot ulcers

MiMedx Group (NASDAQ:MDXG) is up 6% premarket on light volume on the heels of the publication of a study evaluating its dehydrated human umbilical cord (dHUC) for the treatment of chronic diabetic foot ulcers in the International Wound Journal … In the intent-to-treat group, 70% of patients receiving weekly dHUC allograft achieved complete healing by week 12 compared to 48% of those receiving standard-of-care (SOC) treatment for 12 weeks (p=0.0089) … read more